ERBB2 and cancer: Amplifications of ERBB2 and CCND3 were significantly more frequent in ELF3/HNF4A up-regulated gastric cancers (28.6% and 20.4%, respectively) compared with the group of non-up-regulated cancers (2.4% and none, Student’s t-test p = 0.0006 and 0.001, respectively, Fig. 9).